Upgrade to SI Premium - Free Trial

Allogene (ALLO) Reiterated at Market Outperform by Citizens: 'ALPHA3 Trial is On-Track'

August 17, 2026 4:15 AM
Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $6.00 price target on Allogene (NASDAQ: ALLO).The analyst commented, "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments